Abstract
Baseline Characteristics and Interim Safety in RESPOND: A Phase 4 Study in Children with Spinal Muscular Atrophy (SMA) Treated With Nusinersen After Onasemnogene Abeparvovec (P7-9.003)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have